[Acquired entero-vesical fistulas].

T. Longo,A. Inzaghi,G. Cantoni,M. Zappa,R. Marconato

1988-11-15

Minerva Chirurgica

Abstract:

What problem does this paper attempt to address?

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Xuefen Li,Yumiao Xu,Yuejiao Dong,Xianzhi Yang,Bo Ye,Yiyin Wang,Yu Chen

DOI: https://doi.org/10.1016/j.vaccine.2018.03.044

IF: 4.169

2018-01-01

Vaccine

Abstract:Vaccination against hepatitis B virus (HBV) is recommended worldwide. The aim of this study was to assess the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children in the context of protective anti-HBs levels and cellular immune responses. Using a random questionnaire survey, 1695 pre-school children were recruited as research subjects during January 2015 to June 2017. Blood samples were obtained to measure HBV serological markers as well as peripheral immunocytes. The children were divided into non-, low- and hyper- responsive groups (NR, LR, and HR) based on the vaccination efficacy. Additionally, the effect of revaccination on the NR group was evaluated at 1 month after completion of the vaccination course. Among a total of 1695 children, 1591 (93.86%) were infants who were followed while undergoing their primary course of hepatitis B vaccination at the 0-1-6 month schedule, and 1249 (79.30%) of them developed antibodies against HBsAg (anti-HBs) titers greater than 10 IU/L. The results of immunocyte studies indicated that the CD8+ T cells, CD4+CD45RO+ T cells, CD8+CD45RA+ T cells, and T follicular helper (Tfh) cells increased significantly in NR compared with HR. However, lymphocytes, CD4+ T cells, and CD4+CD45RA+ T cells in NR were lower than that in HR. 96 of the non-response cases showed seroprotection after revaccination among 103 cases. Therefore, most of the preschool children who received hepatitis B vaccine in infancy achieved significant seroprotection. Seroconversion rates of individuals revaccinated after initial vaccination failure were significantly higher than those after primary vaccination. Different vaccination efficacy groups showed significant changes in circulating immunocytes, which might be a factor affecting the recombinant HBV vaccine's immune effectiveness.
[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

X Lin,Z Xu,P Ou-Yang

DOI: https://doi.org/10.3760/j.issn:0254-6450.1999.03.013

1999-01-01

Abstract:OBJECTIVETo evaluate the long-term efficacy of hepatitis B(HB) vaccination in newborns and the need for a booster dose. This research is one of the longest HB vaccine follow-up studies in the world with its subjects came from a program of universal infant HB vaccination.METHODSChildren who were born in 1986 and immunized with hepatitis B vaccine at birth were followed up at least once a year. Serum HBsAg, anti-HBc and anti-HBs were tested. At the 5th year after the first dose the prevalence of hepatitis B infection in the children in other district who were also born in 1986 and remained unvaccinated was surveyed as external controls. Random sampling was applied and the possible bias was analyzed. The trends of the positive rates of serum HBsAg, anti-HBs and anti-HBc in the immunized cohort were studied. With external control, the long-term efficacy of HB vaccination was calculated.RESULTSThe positive rates of HBsAg in the vaccine group from the first to eleventh year were 0.46%-0.98% and were below than those of baseline and external control. HBsAg rates in the cohort at different ages were similar with an average of 0.70%(25/3 578). The long-term efficacy of newborn vaccination was 85.42% (95% confidant interval: 70.11%-100%).CONCLUSIONSThe efficacy of HB vaccine was long-lasting and a booster dose was not necessary at least up to age 11 years.
Long-term Efficacy of Infant Hepatitis B Immunization Program

Jian Gong,Rong-cheng Li,Jin-ye Yang,Yan-ping Li,Xiu-rong Chen,Zhi-yi Xu,Chong-bai Liu,Hui-lin Cao,Kai Zhao,Dao-ming Ni

DOI: https://doi.org/10.3760/j.issn:1007-3418.2003.04.004

2003-01-01

Abstract:OBJECTIVE:To evaluate the long-term efficacy of infant hepatitis B (HB) immunization program on preventing hepatitis B virus (HBV) infection, and to assess its impact on the incidence of HB in children.METHODS:Since 1986, the universal HB vaccination for newborn babies with standard, pediatric dose had been launched without serologic prescreening of pregnant women for HBsAg, in a high endemic county of Long-An. A hepatitis surveillance system was set up to evaluate the possible impact on the incidence of hepatitis B. To serologically evaluate the effectiveness of the program, a stratified random sampling of 1000 children in 1987 birth cohorts, who received plasma-derived HB vaccine, was recruited for long-term follow up at the age of 1 to 13 years. A cross-sectional seroepidemiological survey was conducted in the county in 1985, before the program, and in 2001, for 1551 children born in 1996-2000 who were administered yeast recombinant HB vaccine.RESULTS:During the 1 to 13 years after the program, the rates of HBsAg-positive were 0.7% to 2.9% with an average of 1.7% and the protective rates were 83.5% to 96.6%. HBV infection rates were 1.1% tp 5.1% with an average of 2.4% and the protective rates were 93.5% to 98.4%. For the population aged 1 to 4 years who were immunized with recombinant HB vaccine, HBsAg positive rates were 1.8% to 2.4% with an average of 2.0% and the protective rates were 78.4 to 85.2%. 14 years after the program, the cumulative incidence of acute hepatitis B in the children aged 1 to 14 years fell to 1.5 cases per 100,000 children, down 91.8% as compared with that in 1985 to 1987. However, the cumulative incidence of 14.4 cases per 100,000 population in unvaccinated children was not significantly different from that in the history controls. Acute hepatitis B children had not been reported, showing that the vaccination program was 100% protective in children.CONCLUSION:The universal infant HB vaccination program in a hyperendemic area has proved to be effective in controlling HBV infection and decreasing the incidence of acute hepatitis B in children. Booster dose is unnecessary in 13 years after the immunization. The protective efficacy of yeast recombinant HB vaccine is similar to that of plasma-derived HB vaccine.
[Long-Term Efficacy of Vaccination Against Hepatitis B in Newborns: 13 Years' Follow-Up].

W Wu,C Sun,M Jiang,Y Xu,G H Zhang,C B Liu,H L Cao,X M Lin,Z Y Xu

DOI: https://doi.org/10.3760/cma.j.issn.1003-9279.2001.03.012

2001-01-01

Abstract:OBJECTIVE:To evaluate long-term efficacy of hepatitis B vaccination in newborns.METHODS:In the past 13 years we followed up the children who had been immunized with hepatitis B vaccine at birth in 1986 every other year. At each follow-up visit, every child was tested for HBsAg, anti-HBs and anti-HBc.RESULTS:HBsAg positive rate of these birth cohort was low (range between 0.46% and 0.98%) during 13 years' follow-up. Long-term efficacy of the vaccination in preventing HBsAg carriage was confirmed.CONCLUSIONS:Thirteen years later no booster was after needed.
Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program

Thomas J Peto,Maimuma E Mendy,Yamundow Lowe,Emily L Webb,Hilton C Whittle,Andrew J Hall

DOI: https://doi.org/10.1186/1471-2334-14-7

2014-01-07

Abstract:Background: Gambian infants were not routinely vaccinated against hepatitis B virus (HBV) before 1986. During 1986-90 the Gambia Hepatitis Intervention Study (GHIS) allocated 125,000 infants, by area, to vaccination or not and thereafter all infants were offered the vaccine through the nationwide immunisation programme. We report HBV serology from samples of GHIS vaccinees and unvaccinated controls, and from children born later. Methods: During 2007-08, 2670 young adults born during the GHIS (1986-90) were recruited from 80 randomly selected villages and four townships. Only 28% (753/2670) could be definitively linked to their infant HBV vaccination records (255 fully vaccinated, 23 partially vaccinated [1-2 doses], 475 not vaccinated). All were tested for current HBV infection (HBV surface antigen [HBsAg]) and, if HBsAg-negative, evidence of past infection (HBV core-protein antibody [anti-HBc]). HBsAg-positive samples (each with two age- and sex-matched HBsAg-negative samples) underwent liver function tests. In addition, 4613 children born since nationwide vaccination (in 1990-2007) were tested for HBsAg. Statistical analyses ignore clustering. Results: Comparing fully vaccinated vs unvaccinated GHIS participants, current HBV infection was 0.8% (2/255) vs 12.4% (59/475), p < 0.0001, suggesting 94% (95% CI 77-99%) vaccine efficacy. Among unvaccinated individuals, the prevalence was higher in males (p = 0.015) and in rural areas (p = 0.009), but adjustment for this did not affect estimated vaccine efficacy. Comparing fully vaccinated vs unvaccinated participants, anti-HBc was 27.4% (70/255) vs 56.0% (267/475), p < 0.00001. Chronic active hepatitis was not common: the proportion of HBsAg-positive subjects with abnormal liver function tests (ALT > 2 ULN) was 4.1%, compared with 0.2% in those HBsAg-negative. The prevalence of antibodies to hepatitis C virus was low (0.5%, 13/2592). In children born after the end of GHIS, HBsAg prevalence has remained low; 1.4% (15/1103) in those born between 1990-97, and 0.3% (9/35150) in those born between 1998-2007. Conclusions: Infant HBV vaccination achieves substantial protection against chronic carriage in early adulthood, even though approximately a quarter of vaccinated young adults have been infected. This protection persists past the potential onset of sexual activity, reinforcing previous GHIS findings of protection during childhood and suggesting no need for a booster dose. Nationwide infant HBV vaccination is controlling chronic infection remarkably effectively.
An observation on the long-term efficacy of recombinant hepatitis B vaccines among the newborns

Xiao-lian DONG,Zhi-feng TANG,Xue-cai WANG,Ying-feng CHEN,Sheng-yu CHEN,Xiao-li WANG,Jian-liang FAN,Ying-jie ZHENG

DOI: https://doi.org/10.19485/j.cnki.issn1007-0931.2017.05.002

2017-01-01

Journal of Preventive Medicine

Abstract:Objective evaluate the long-term efficacy of the recombinant hepatitis B vaccines (HBV) among the newbornswith vaccination at birth. Methods During 1996-1997, 135 newborns were selected from Deqing according to the inclusioncriterion. They were divided into 2 groups: a group of 35 newborns whose mother was HBsAg positive) and a group of 100newbornswhose mother was HBsAg negative. All 135 newborns routinely received 3 doses of yeast -derived hepatitis Bvaccines (i.e. the first dose at birth, the second dose at 1 month old, and the third dose at 6 months old) . Serologicalmarkers to HBV were repeatedly assessed at 3 follow-up stages (i.e. the first follow-up at 12 months, the second follow-upat 2010, the third follow-up at 2012) . Results Participants remained in the study at 3 follow-upstages were 123(91.11%), 95(70.37%) and 46(34.07%) respectively. Participants' serum HBsAg were negative at all 3 follow-upstages. Among participants whose mothers were HBsAg positive, 3 participants were found to be HBcAb positive in 2010,and no new HBcAb positive participants were found in 2012. The rates of HBsAb positive at 3 follow-up stages were 88.89%, 81.48%, and 80.00% respectively. The HBsAb geometric mean concentrations (GMCs) of participants at their 12 monthsold were significantly positively associated with those in 2010 and those in 2012(P<0.05) . Among participants whosemothers were HBsAg negative, no HBcAb positive participants were found. The rates of HBsAb positive at 3 follow-up stageswere 91.18%, 54.41%, and 52.78% respectively. No correlation was found among HBsAb GMCs of participants at 12 monthsold, in 2010 and in 2012. No correlation was found between boost vaccination and the rate of HBsAg positive, afteradjustment of the HBsAg status of their mothers. Conclusion The efficacy of the yeast-derived HBV could sustain for at least13-15 years, and the general population do not need booster immunization. After the 3-dose immunization, the HBsAblevels of the healthy mothers' 12-months-old children were related to those of their adolescence.
Long-term Effect of Plasma-derived Vaccine in the Prevention of Hepatitis B (eighteen Years'Follow-up Study)

吴维寿,孙超美,姜铭波,张国华,周宁,欧阳佩英,汪萱怡,徐志一

DOI: https://doi.org/10.3969/j.issn.1006-916x.2005.03.010

2005-01-01

Abstract:Objective To evaluate the long-term effectiveness of the universal infant HBV immunization in Shanghai. Method The 1986 birth cohort who received HBV vaccine was followed every 1-2 years during 1986-2004. Blood specimens were collected and tested for HBsAg, anti-HBS, and anti-HBC. Results The HBV vaccine coverage rate was around or over 95%.In the 11 follow-ups studies in 18 years, 5332 blood specimens were collected and tested.The HBsAg sero-positivity rate is 1%. The average positivity of HBsAg is 0.62%, if shows that HBsAg positivity rate decreased. Compared to the HBsAg positivity rate before the immunization program,the long-term effectiveness was thus estimated at 93.64%(95%CI:92.51%-94.78%).The rate of the vaccinated subjects with anti-HBs of≥10mIU/mL, declined form 89% in 1987 to 30.1% in 2004. Conclusion This decline, however,had no impact on the HBsAg carrier rate in the immunized cohort and thus is not an indicator for revaccination.
Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

Rui Yanjing,Dai Yimin,Zheng Yaning,Ning Mingzhe,Xu Zhiye,Wang Zhiqun,Hu Yali,Zhou Yihua

DOI: https://doi.org/10.3760/cma.j.issn.2095-428x.2018.22.011

2018-01-01

Abstract:Objective To evaluate the long-term efficacy of neonatal immunoprophylaxis in children born from mothers infected with hepatitis B virus (HBV),and to clarify whether a booster vaccination is required.Methods Totally 252 children of HBV infected mothers,who were negative for hepatitis B surface antigen (HBsAg) tested in Nanjing Drum Tower Hospital in 2012,were enrolled to participate in this study from July to September,2017.Revaccination of hepatitis B vaccine was recorded and other relevant informations were collected.HBV serologic markers were detected in each child.Results Totally 198 children (78.6％) were followed up.They were (8.4 ± 2.2) years old and 112 cases were boys.All 198 children were negative for both HBsAg and hepatitis B core antibody (anti-HBc).The overall positive rate of hepatitis B surface antibody (anti-HBs) (≥ 10 IU/L) was 65.7％.During period of 2012 to 2017,53 children were boosted with hepatitis B vaccine.Their median anti-HBs titer in 2017 was higher than that in 2012 (327.95 IU/L vs.158.01 IU/L),and the difference was significant (Z =-4.480,P ＜0.05).The other 145 children were not revaccinated,their median anti-HBs titer was decreased from 214.19 IU/L in 2012 to 70.49 IU/L in 2017,and the difference was significant (Z =-6.575,P ＜ 0.05).Of 145 children who were not revaccinated,25 cases had anti-HBs levels ＜ 10 IU/L and 120 cases ≥ 10 IU/L in 2012,and the other 47 cases also showed the antibody ＜ 10 IU/L in 2017,but none of them was infected with HBV.Conclusions Neonatal immunoprophylaxis in infants from HBV-infected can provide long-term protection against hepatitis B.The children with anti-HBs ＜ 10 IU/L are still immune to HBV and booster vaccination for them seems unnecessary.
[Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among low-responder infants following primary vaccination: 4-year of follow-up]

J J Lyu,B Y Yan,J Y Liu,Y Feng,W L Wu,X F Liang,F Q Cui,F Z Wang,G M Zhang,A Q Xu,L Zhang

DOI: https://doi.org/10.3760/cma.j.issn.0253-9624.2017.06.007

2017-06-06

Abstract:Objective: Assess the 4-year antibody against hepatitis B surface antigen (anti-HBs) persistence after revaccination with 3-dose of hepatitis B vaccine (HepB) among low-responder infants following primary vaccination. Methods: According to stratified cluster sampling, a total of 4 147 infants were enrolled and primarily vaccinated with 5 μg HepB derived in Saccharomyces Cerevisiae (HepB-SC) at 0-1-6 months schedule from 75 towns of Jinan, Weifang, Yantai, Weihai prefectures, Shandong Province, China in Aug and Sep 2009. Blood samples were collected one to six months after the third dose of primary immunization and tested for anti-HBs using chemiluminescence microparticle immunoassay (CMIA). 717 infants who appeared low response (10 mU/ml ≤ anti-HBs<100 mU/ml) were revaccinated with 3-dose of HepB. Blood samples were collected from a total of 315 infants one month (T(0)), four years (T(1)) after revaccination and anti-HBs, antibody against hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) were detected by CMIA. Information about their birth, primary vaccination were collected. The risk factors associated with positive rate of anti-HBs and GMC of anti-HBs were identified by multiple non-conditional logistic regression analysis and multifactor linear regression model analysis, respectively. Results: Among 315 children, 165 (52.38%) were male and 150 (47.62%) were female. The positive rate was 83.81% (264/315) at T(0) and it decreased to 16.51% (149/529) at T(1). The corresponding GMC decreased from 473.15 mU/ml to 17.37 mU/ml. The average annual decreasing rate of positive rate and GMC was 33.38% and 56.23% from T(0) to T(1). Multivariable analysis showed the positive rate and GMC among those whose anti-HBs titer higher at T(0) were significantly higher at T(1). The positive rate at T(1) among those whose anti-HBs titer 400-<600, 600-<800, 800-<1 000, ≥1 000 mU/ml at T(0) were significantly higher than those whose anti-HBs titer less than 200 mU/ml. The OR (95%CI) of the positive rate was 4.29 (1.03-17.84), 4.53 (1.25-16.47), 4.19 (1.10-15.97) and 9.13 (2.91-28.63), respectively. The GMC at T(1) among those whose anti-HBs titer 400-<600, 600-<800, 800-<1 000 mU/ml and those whose anti-HBs titer ≥1 000 mU/ml at T(0) were higher than those whose anti-HBs titer<200 mU/ml. The b value (95% CI) of GMC was 0.84 (0.06-1.62), 1.13 (0.46-1.79), 1.33 (0.65-2.01) and 1.88 (1.33-2.44), respectively. GMC among full-term infants were significantly higher than premature infants at T(1). The b value (95% CI) of GMC was 0.86 (0.04-1.68). Conclusion: Anti-HBs GMC decreased rapidly 4 years after revaccination among low-responder infants, but still kept good protection. The anti-HBs persistence after revaccination was associated with anti-HBs level of titer one month after revaccination.
Prevention of vertical transmission of hepatitis B: A retrospective review of a 5-year maternal-infant cohort in London

Elizabeth O'Mahony,Sophie Raghunanan,Ashley Brown,Caroline Foster

DOI: https://doi.org/10.1111/jpc.16609

2024-07-02

Abstract:Aims: The World Health Organization (WHO) estimates that 3.5% of the population live with hepatitis B virus (HBV); migrants to Europe are disproportionately affected. UK birth dose HBV vaccination is limited to infants born to those living with HBV (LWHBV). High-risk infants (high maternal infectivity, low birthweight) also receive HBV immunoglobulin (HBIG). The Family Hepatitis Clinic follows infants and those LWHBV working towards WHO goals of combating viral hepatitis by 2030. Methods: A trust-wide electronic note review of outcomes for infants born to those LWHBV (2016-2020). Results: Two hundred and eighty-three infants, 134 (47%) females, born to those LWHBV were referred. Two hundred and thirty-one (82%) attended follow-up with a vertical transmission rate of 0%. Twenty (7%) individuals LWHBV received tenofovir disoproxil fumerate in pregnancy; median viral load (VL) at initiation 125 416 376 DNA IU/mL, one having birth VL. Twenty-eight (10%) infants were stratified as high risk and all received HBIG and birth dose vaccination with 9 (32%) subsequently lost to follow-up, compared to 48 (19%) low-risk infants. 267/283 (94%) had birth dose vaccination documented and 206/283 (73%) received at least four vaccine doses. 215/283 (76%) infants had serology by 24 months; 17 (6%) with suboptimal vaccine responses: hepatitis B surface antibody <100 IU/mL. Serology before 18 months resulted in higher rates of maternal hepatitis B core antibody detection (15% vs. 3%). Conclusion: Prevention of vertical transmission of HBV was universal in those attending, although high-risk infants were more likely lost to follow up. HBV post-vaccine serological protection was comparable with national data from 2021 (77% >4 doses, 77% HBsAb >100).
Effectiveness of a bivalent Haemophilus influenzae type B-hepatitis B vaccine in preventing hepatitis B virus infection among children born to hepatitis B e antigen-positive carrier mothers

Richard Doherty,Suzanne Garland,Martin Wright,Monique Bulotsky,Charles Liss,Hassan Lakkis,Alexander Nikas,Walter Straus

DOI: https://doi.org/10.1097/INF.0b013e3181a06fad

Abstract:Background: This observational study evaluated a modified immunoprophylactic regimen (hepatitis B immune globulin [HBIG]) and a dose of thimerosal-free monovalent hepatitis B (HB) vaccine shortly after birth followed by doses of thimerosal-free bivalent Haemophilus influenzae type b (Hib)-HB vaccine at 2 and 4 months of age, and a booster at 12 months of age) in infants at high risk of hepatitis B virus (HBV) infection (mothers HBeAg+). Methods: Children >or=6 months of age vaccinated in routine clinical practice were tested twice (>or=6 months apart) for HBV antigens surface antigen (HBsAg) and "e" antigen, and for antibody to HBsAg. Partial nucleotide sequence analysis was performed on HBV DNA isolated from infants identified with a breakthrough chronic HBV infection. A fully sequential statistical design was used to maximize patient safety and study efficiency. Results: Four of 60 children developed chronic HBV infection despite vaccination, but at no point did the cumulative number of cases reach the boundary of statistical significance. Overall, the analysis adjusted for sequential testing yielded an estimated breakthrough rate of 6.7% (90% CI: 2.3%-14.6%). In a subset of uninfected children tested for antibody to HBsAg 1 to 4 months after the second dose of Hib-HB vaccine, 90% (9/10) had >or=10 milli-International Units per milliliter (mIU/mL). The third dose of Hib-HB vaccine induced a secondary increase in the level of antibody; 94.7% (18/19) of a second group developed >or=100 mIU/mL, with a geometric mean concentration of 771 mIU/mL (95% CI: 351.4-1692.1 mIU/mL). Conclusion: The tested regimen is comparably effective to historical experience with a standard one employing HBIG plus monovalent thimerosal-containing HB vaccine given at 0, 1, and 6 months of age.
The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

Lan-ying XU,Jian-xun LIU,Zhan-jun CHANG,Jie LI,Ya-lin LIU,Hui ZHUANG,Gui-zhi CHENG,Hong-xia WEI,Wei-qing CHEN,Li-min WANG,Zhi-min HU

2017-01-01

Abstract:Objective To provide a scientific basis for making booster immunization strategy and explore the antibody persistence of immunization with hepatitis B vaccine (YDV,10μg,at the age of 0,1,and 6 months) combined with different doses of hepatitis B immunoglobulin (100IU or 200IU) in 3 years among infants born by hepatitis B surface antigen positive mothers.Methods To observe the dynamic change and persistence of antibody among infants,titers of the antibody against hepatitis B surface antigen (anti-HBs) were detected respectively among children at the age of 7 months,1,2 and 3 years after the primary vaccination.Results Children's no,low,normal and high antibody response rates were 0.76％,5.34％,38.17％,53.18％ (2.54％ infected with HBV) by 7 months,which changed to 25.13％,44.67％,18.73％ and 7.68％ (3.79％ infected with HBV) respectively by 3 years old,the difference was statistically significant (P ＜ 0.001).The rate of low and cumulative no antibody response rate was 69.80％ at the age of 3 years.The GMC of anti-HBs dropped to 59.06m IU/ml by three years old from 997.56mIU/ml at the age of seven months (P ＜ 0.001) in the following-up periods.There were three new HBV infections by three years old among the children (3/429),with low,normal or high antibody response to hepatitis B primary vaccination respectively at the age of 7 months.Conclusion The study results suggest that serological markers of HBV should be tested on a regular basis among children born by hepatitis B surface antigen positive mothers,and after 1 or 2 years,immunity should be strengthened with supplementary HBV vaccination.
Follow-up Study on Efficacy of Blocking Mother-to-infant Transmission of HBV and Its Influence Factors in Jiangsu Province, 2010-2015

J Jiang,S L Dai,J F Xu,Y Zou,L G Zhu,H Peng,F C Zhu,X J Zhai

DOI: https://doi.org/10.3760/cma.j.issn.0254-6450.2016.10.006

2016-01-01

Abstract:Objective To evaluate the effects of blocking transmission of HBV from mother to infant in Jiangsu,and discuss influencing factors related to development of chronic HBV infection in children of HBsAg positive mother.Methods HBsAg positive mothers delivered during 2010-2015 in three counties of Jiangsu (Zhangjiagang,Danyang and Taixing) and their neonates were included in the study.The neonates were vaccinated with hepatitis B vaccine (10 μg) and hepatitis B immunoglobin (100 units) within 24 hours after birth.Blood samples were collected from the infants 7 months later,and serum HBsAg,anti-HBs and anti-HBc were detected by Abbott particles chemiluminescence.Results A total of 2 099 children aged 7-52 months were surveyed,of whom 34 (1.62％) developed chronic HBV infection.Logistic regression analysis showed that mother HBeAg positivity (RR=4.997,95％CI:2.408-10.370) was the independent risk factors of mother-to-infant transmission of HBV,while elder delivery age (RR=0.264,95％CI:0.101-0.691) was independent protective factors of HBV transmission.Among the other 2 065 uninfected children,9.7％ had anti-HBs level less than 10 mIU/ml,35.4％ between 10 and 100 mIU/ml,and 54.9％ higher than 100 mIU/ml.The anti-HBs positive rate was 90.3％ and the anti-HBc positive rate was 13.7％.The positive rate and geometric mean titers (GMT) of anti-HBs reached the peaks at 7-12 months after birth,and decreased with the age.Conclusions The current immunological strategy of Jiangsu has good protective efficacy for the interruption of perinatal transmission of HBV.Mother HBeAg positivity is the major risk factor for perinatal blocking failure.Children with effective immunization still need to be monitored for anti-HBs and revaccinated if necessary.
Evaluation of dental injury following endotracheal intubation using the Periotest technique.

J. Hoffmann,C. Westendorff,S. Reinert

DOI: https://doi.org/10.1111/J.1600-9657.2005.00318.X

2005-10-01

Dental Traumatology

Abstract:The hazards of damage to teeth and their periodontal attachment during tracheal intubation are well known. Dental trauma represents the commonest single reason for complaints against anesthesiologists. In order to predict the possible risk of perianesthetic iatrogenic tooth luxation we evaluated the use of a measuring method (Periotest technique), being well established for the diagnosis of periodontal disease. In 120 patients undergoing elective surgery, we compared the amount of tooth mobility before and after general anesthesia to different scores assessing the difficulty of tracheal intubation. Furthermore, the level of work experience of the intubating anesthetist was compared with the degree of postoperative tooth mobility. Changes of periodontal attachment could not be detected by the Periotest technique. The Periotest technique does not seem to have the ability to detect early periodontal changes associated with endotracheal intubation.
Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Yan Qiu,Jing-Jing Ren,Zi-Kang Wu,Ling-Zhi Shen,Huan Shan,Xue-Wei Dai,Jing Li,Ying Liu,Wen Ren,Jun Yao,Lan-Juan Li

DOI: https://doi.org/10.1080/21645515.2020.1738169

2020-01-01

Human Vaccines & Immunotherapeutics

Abstract:Debate continues regarding the need for a booster vaccination in children who received a universal infant hepatitis B virus (HBV) vaccination. The aim was to explore the need and the strategies for the booster HBV vaccination. 8-year prospective cohort study was conducted among children aged 5–15 years in 2009–2010 in Zhejiang Province. The participants were divided into groups A (<0.1 mIU/mL), B (0.1 to < 1 mIU/mL) and C (1 to <10 mIU/mL) according to the pre-booster anti-HBs antibody levels. 5 μg (group I), 10 μg (group II), 20 μg hepatitis B vaccines (group III) or 5 μg hepatitis A and B (HAB) vaccines (group IV) with 0-1-6-month schedule were randomly administered to children negative for all markers. Blood samples were collected at baseline HBV marker testing, 1 month after the first dose, 1 month, 1 year, 5 years and 8 years after the third dose. Among 4170 children, 2326 (55.8%) were negative for all HBV markers. Group II showed the highest seropositive rates of 92.8%, 99.7%, 97.6%, 90.3% and 83.4% with GMTs of 4194.5 mIU/ml, 4163.9 mIU/ml, 466.9 mIU/ml, 190.6 mIU/ml, 122.6 mIU/ml from 1 month after dose 1 to 8 years after dose 3, respectively (P < .01). Participants in group C showed seropositive rates of 98.9%, 99.9%, 99.5%, 95.5%, 92.8% after the revaccination with GMTs of 6519.6 mIU/ml, 5267.4 mIU/ml, 547.1 mIU/ml, 249.5 mIU/ml, 155.3 mIU/ml, respectively, higher than group A and B (P < .001), except 1 month after the third dose. The 10 μg of HBV vaccine with a 0-1-6-month booster regimen may elicit robust responses and persist for 8 years or longer. Additionally, 1-dose revaccination maybe suitable for children with 1 to < 10 mIU/ml anti-HBs titers.
Long-term Evaluation of Immune Efficacy among Newborns 16 Years after HBV Vaccination

周建军,吴维寿,孙超美,戴红勤,周宁,刘崇柏,曹惠霖,汪萱怡,徐志一

DOI: https://doi.org/10.3969/j.issn.1006-916X.2003.03.001

2003-01-01

Abstract:In order to investigate the long-term immune efficacy for newborns after plasma-derived HBV vaccination and to decide whether the booster vaccination is necessary or not,we followed up the children,at least once biennially,who were born in 1986 in former Nanshi District of Shanghai and had received plasma-derived HBV vaccine at birth.Their blood samples were tested for HBsAg,Anti-HBs and Anti-HBc.Results showed that within the period of 16 years,their positive rate for HBsAg ranged between 0.46%～0.97%,the average being 0.61%(95% confidence interval between 0.39%～0.83%),which was much lower than those of the background group before vaccination and the external group.The long term protective rate of the vaccine was an average of 82.06%(95% confidence interval between 73.45%～91.83%).In conclusion,the newborns who had been vaccinated completely by the plasma-derived HBV vaccine at their birth are unnecessary to take the booster again within 16 years.
Evaluation of Long Term Efficacy of Hepatitis B Vaccination

李荣成,龚健,杨进业,王树声,李艳萍,陈修荣,黄兆能,徐志一,刘崇柏,曹惠霖,夏国良,赵铠,倪道明

DOI: https://doi.org/10.3969/j.issn.1673-758x.2002.05.001

2002-01-01

Abstract:Objective To evaluate the long term effectiveness of preventive HBV infection and to monitor the incidence of hepatitis B in children to see possible impact on the program of Long An that was launched in 1986.Methods (1)Set up a surveillance system of hepatitis,to evaluate the possible impact on incidence of hepatitis B.(2) To serologically evaluate the effect of the program, a stratified random sampling of 1000 chidren in 1987 birth cohorts was recruited for long term follow up at the age 1_13 years.(3) Cross_sectional seroepidemiolgical survey was carried out in the county in 1985 before the program and 10 years later. HBsAg, anti_HBs and anti_HBc were tested by RIA. Results The average coverage of hepatitis B vaccine was 89.1%.At 13 years after vaccination, the seropositivity for HBsAg in children has decreased from 16.0% to 2.3%,the annual effectiveness was 89.7%.HBV accumulated infection rate was 3.5%,protective rate was 96.2%.The incidence of acute hepatitis B was 1.60 per 100,000 in children aged 1-13 years, it decreased by 91.3% as compared with the incidence of 18.38 per 100,000 in same age group in 1985-1987.Conclusion Mass hepatitis B vaccination program in Long An County has proved to be effective in control of HBV chronic infection and incidence of acute hepatitis B in childhood.
The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Zikang Wu,Jun Yao,Hongdan Bao,Yongdi Chen,Shunshun Lu,Jing Li,Linna Yang,Zhenggang Jiang,Jingjing Ren,Kai-Jin Xu,Bing Ruan,Shi-Gui Yang,Tian-Sheng Xie,Qian Li

DOI: https://doi.org/10.1080/21645515.2018.1426419

2018-01-01

Human Vaccines & Immunotherapeutics

Abstract:The aim of this study was to evaluate changes in hepatitis B surface antibody titers (anti-HBs) after booster vaccinations in children aged 5-15 y and to provide suitable immunization strategies. A total of 2208 children were initially enrolled in screening, and 559 children were finally included. The participants were divided into 2 groups according to their pre-booster anti-HBs levels: Group I, <10mIU/ml and Group II, 10mIU/ml. Group I was administered 3 doses of booster hepatitis B vaccine (0-1-6months, 10g), and Group II was administered 1 dose of booster hepatitis B vaccine (10g). The antibody titer changes were examined at 4 time points: 1month after dose 1 and dose 3, and 1year and 5years after dose 3. The protective seroconversion rates at those points were 95.65%, 99.67%, 97.59% and 91.05% (p < 0.001), respectively, in Group I, and 100.00%, 99.87%, 99.66% and 98.21% ((2) = 6.04, p = 0.11), respectively, in Group II. The GMT in subjects aged 5-9y were higher than that in subjects aged 10-15y in both Group I and Group II at 1month after dose 1, but no difference was observed at the other three time points. This study demonstrates that booster vaccination has a good medium-term effect. A booster dose for subjects with protective antibodies is not necessary but effective, and 3 doses of hepatitis B vaccination are recommended for those who have lost immunological memory. Receiving booster immunization at the age of10-15years may be more appropriate for individuals living in HBV high epidemic areas
A Long-term Follow-up of Hepatitis B Vaccine Inoculated and HB Immunoglobulin Combinely Immunized Infants Born to HBsAg Positive Mothers

Jian-she WANG,Qi-rong ZHU

DOI: https://doi.org/10.3969/j.issn.1006-916X.2001.02.012

2001-01-01

Abstract:In order to investigate the occurrence of chronic hepatitis B virus(HBV) infection in HB vaccine inoculated infants born to HBsAg positive mothers and its affecting factors and also to study the effect of combined use of HB immunoglobulin (HBIG) and HB vaccine on the blocking of perinatal transmission of HBV, we divided 624 infants born to HBsAg positive mothers into two groups randomly. The first group of infants were simply vaccinated with HB vaccine 20μg at,0, 1, 6 months old. The second group of infants were inoculated with HBIG 100 IU at their birth and further vaccinated with HB vaccine 20μg at 1,2,7 months old. The HBsAg of the two groups of infants was tested at the age of 1,3,6,12,18,24 months old and every year by EIA. They were all followed up for 6.34±1.71 years averagely. The follow-up results showed that there were 89 childeren infected chronically by HBV, among them 82% appeared to be HBsAg positive, firstly seen before the age of 6 months mainly attributing to uterus infection. The HBV chronic infection rate of infants born to HBsAg, HBeAg positive mothers (HB vaccine immunized, 24.5%; HBIG+HB vaccine, 10.6%, P<0.005) was higher than that of infants born to HBsAg positive mothers (HB vaccine immunized, 10.7%; HBIG+HB vaccine 3.8%, P<0.025). Moreover, the chronicity rate of the infants whose HBsAg firstly appeared within 6　　months and were born to HBsAg, HBeAg positive mothers was higher than that of the infants born to HBsAg positive months (68%,40% respertively in HB vaccine inoculated group, P<0.025). Infants immunized combinely with HBIG and HB vaccine had their chronic HBV infection decreased from 17.6% to 5.0% at l year old as compared with that of HB vaccine inoculated infants. The total chronic HBV infection rate in children born to HBsAg, HBeAg positive mothers decreased from 24.5% to 10.6% (P<0.005) and that in children born to HBsAg positive mothers decreased from 10.7% to 3.8% (P<0.025). The HBV chronicity rate of HBsAg positive infants born to HBsAg, HBeAg positive mothers also decreased and that of infants born with HBsAg negative, but became positive after 1-6 months decreased from 40.9% to 0% (P=0.0315). The HBsAg seronegative conversion rate in l month old infants born to HBsAg positive mothers increased from 26.4% to 58.8% (P<0.025). All these data indicated that infants born to HBsAg positive mothers, though had been HB vaccine immunized, still had chronic infection, that was chiefly due to chronic uterus infection by HBV. The single use of HB vaccine can not completely block the uterus infection of HBV, but when combinatively used with HBIG, the blocking effect is more efficient, the chronicity of HBV infection also can be avoided.
Evaluation of antibody persistence after a four-dose primary hepatitis B vaccination and anamnestic immune response in children under 6 years

Miniar Tfifha,Saoussen Kacem,Mohamed Ben Rejeb,Said Naija,Noureddine Boujaafar,Saoussen Abroug,Abdelhalim Trabelsi

DOI: https://doi.org/10.1099/jmm.0.001086

Abstract:Introduction. Tunisia is an intermediate hepatitis B virus (HBV) endemic country. The vaccination against hepatitis B was introduced in 1995 including four doses with a first dose administrated at birth. Decreasing the level of antibodies against hepatitis B surface antigen (anti-HBs) over time can be alarming. This study was conducted to explore the anti-HBV immune response among children under 6 years old, vaccinated according to the national vaccination schedule, by evaluating the immunological response to primary vaccination and by exploring the anamnestic immune response to a booster dose.Methods. We conducted a cross-sectional prospective study from June 2016 to June 2017 (n=180), based on voluntary participation. Children were recruited from the public pediatric ward sectors in Sahloul University Hospital of Sousse in Central Tunisia. An anti-HB titre was determined based on electro-chemiluminescence micro-particle immunoassay (ECLIA), using Elecsys Anti-HBs II kit, Roche.Results. Mean age at the time of enrollment in the study was 33±14.8 months. The seroprotection rate was 77.2 %. The anti-HB titre differed significantly between the different age groups (P=0.002). The predicting variable for having no seroprotective antibody level was older age. Children with anti-HB levels <10 IU l- 1 were offered an additional dose of HBV vaccine. Anamnestic response 1 month after the challenge dose was observed in 100 % of subjects. The probability of developing a high antibody response, following the booster dose increased in conjunction with an increased pre-booster antibody level.Conclusion. The response to a booster dose suggests the persistence of immune memory in almost all vaccinated individuals. Although a booster dose increases substantially anti-HB titre, the clinical relevance of such an increase remains unknown.

[Acquired entero-vesical fistulas].

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

Long-term Efficacy of Infant Hepatitis B Immunization Program

[Long-Term Efficacy of Vaccination Against Hepatitis B in Newborns: 13 Years' Follow-Up].

Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program

An observation on the long-term efficacy of recombinant hepatitis B vaccines among the newborns

Long-term Effect of Plasma-derived Vaccine in the Prevention of Hepatitis B (eighteen Years'Follow-up Study)

Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

[Anti-HBs persistence after revaccination with three doses of hepatitis B vaccine among low-responder infants following primary vaccination: 4-year of follow-up]

Prevention of vertical transmission of hepatitis B: A retrospective review of a 5-year maternal-infant cohort in London

Effectiveness of a bivalent Haemophilus influenzae type B-hepatitis B vaccine in preventing hepatitis B virus infection among children born to hepatitis B e antigen-positive carrier mothers

The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

Follow-up Study on Efficacy of Blocking Mother-to-infant Transmission of HBV and Its Influence Factors in Jiangsu Province, 2010-2015

Evaluation of dental injury following endotracheal intubation using the Periotest technique.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Long-term Evaluation of Immune Efficacy among Newborns 16 Years after HBV Vaccination

Evaluation of Long Term Efficacy of Hepatitis B Vaccination

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

A Long-term Follow-up of Hepatitis B Vaccine Inoculated and HB Immunoglobulin Combinely Immunized Infants Born to HBsAg Positive Mothers

Evaluation of antibody persistence after a four-dose primary hepatitis B vaccination and anamnestic immune response in children under 6 years